TQH3906 / Sino Biopharm - LARVOL DELTA

Efficacy and Safety of TQH3906 in Patients with Plaque Psoriasis: 12-week Results From a Phase 2, Randomized, Placebo-controlled Study (EADV 2026) - No abstract available

Clinical • P2 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

TQH3906-III-01: A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=400 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P3 trial • Dermatology • Immunology • Psoriasis

TQH3906-II-02: A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis (clinicaltrials.gov) - P2 | N=156 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2026 ➔ Jul 2026

Enrollment open • Trial initiation date • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

TQH3906-II-03: A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=198 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Phase Ib Study of TQH3906 Capsule for the Induction Therapy of Moderate to Severe Active Ulcerative Colitis (AOCC-IMKASID 2026) - P1 | "TQH3906, the first efficacious TYK2/JAK1 allosteric inhibitor for ulcerative colitis, demon- strates favorable tolerability and safety. Preliminary efficacy has been observed, with the high-dose cohort (48mg) study currently ongoing. Keywords: TYK2/JAK1 Allosteric Inhibitor, Immune-mediated Inflammatory Disorder, Ulcerative Colitis"

P1 data • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Plaque Psoriasis • Psoriasis • Respiratory Diseases • Ulcerative Colitis • JAK1 • TYK2

TQH3906-II-01: Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=209 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis • IL17A

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers (clinicaltrials.gov) - P1 | N=96 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis • IL18

TQH3906-Ib-01: Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease (clinicaltrials.gov) - P1 | N=135 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Dec 2026 ➔ Jul 2027

Enrollment open • Trial primary completion date • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=198 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis (clinicaltrials.gov) - P2 | N=156 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P2 trial • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

TQH3906-II-01: Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=209 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Sep 2026 ➔ Dec 2025 | Trial primary completion date: Feb 2026 ➔ Nov 2025

Trial completion • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

TQH3906 'TYK2/JAK1 JH2 Allosteric Inhibitor' Achieving Positive Progress in the Phase II Clinical Trial for Plaque Psoriasis (HKEXnews) - "The study ultimately enrolled 209 patients, divided into a placebo group and five distinct TQH3906 dose groups, with doses administered orally once daily. In terms of efficacy, TQH3906 demonstrated a favorable dose-response relationship and reached a pharmacodynamic plateau for the primary endpoint. At the anticipated recommended Phase II dose (RP2D), after 12 weeks of treatment, the PASI 75 (≥75% improvement in Psoriasis Area and Severity Index from baseline) response rate exceeded 90% and the PASI 90 (≥90% improvement) response rate exceeded 70%, significantly outperforming the placebo group (approximately 10% and 5%, respectively)....Detailed data from this study will be presented at upcoming international academic conferences."

P2 data • Psoriasis

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers (clinicaltrials.gov) - P1 | N=96 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Apr 2025 | Trial primary completion date: Jun 2024 ➔ Apr 2025

Trial completion • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

TQH3906-II-01: Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=210 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=120 ➔ 210 | Trial completion date: Sep 2025 ➔ Sep 2026 | Trial primary completion date: Jan 2025 ➔ Feb 2026

Enrollment change • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

TQH3906-Ib-01: Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease (clinicaltrials.gov) - P1 | N=116 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

TQH3906-II-01: Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P2 trial • Dermatology • Immunology • Psoriasis

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers (clinicaltrials.gov) - P1 | N=76 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis